Antidepressant studies in Parkinson's disease: A review and meta‐analysis

The objective of this study was to determine effect sizes for both antidepressant treatment and placebo for depression in Parkinson's disease (PD), and to compare the findings with those reported in elderly depressed patients without PD. Recent reviews have concluded that there is little empiric evidence to support the use of antidepressants in PD; however, available data has not been analyzed to determine the effect size for antidepressant treatment in PD depression. A literature review identified antidepressant studies in PD. Suitable studies were analyzed using meta‐analytic techniques, and effect sizes were compared with those from antidepressant studies in elderly patients without PD. Large effect sizes were found for both active treatment and placebo in PD, but there was no difference between the two groups. In contrast, active treatment was superior to placebo in depressed elderly patients without PD. In PD, increasing age and a diagnosis of major depression were associated with better treatment response. Results also suggest that newer antidepressants are well tolerated in PD. Despite the high prevalence of depression and antidepressant use in PD, controlled treatment research has been almost nonexistent. Meta‐analysis results suggest a large but nonspecific effect for depression treatment in PD. In addition, PD patients may benefit less from antidepressant treatment, particularly selective serotonin reuptake inhibitors, than do elderly patients without PD. © 2005 Movement Disorder Society

[1]  C. Clarke,et al.  Systematic review of antidepressant therapies in Parkinson's disease. , 2003, Parkinsonism & related disorders.

[2]  Daniel Weintraub,et al.  Recognition and Treatment of Depression in Parkinson's Disease , 2003, Journal of geriatric psychiatry and neurology.

[3]  K. Krishnan,et al.  An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. , 2003, The American journal of psychiatry.

[4]  A. Leentjens,et al.  SSRIs in the treatment of depression in Parkinson's disease , 2003, International journal of geriatric psychiatry.

[5]  J. Marinus,et al.  The contribution of somatic symptoms to the diagnosis of depressive disorder in Parkinson's disease: a discriminant analytic approach. , 2003, The Journal of neuropsychiatry and clinical neurosciences.

[6]  R. Roos,et al.  Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa. , 2002, British journal of clinical pharmacology.

[7]  A. Stoessl,et al.  The placebo effect in Parkinson's disease , 2002, Trends in Neurosciences.

[8]  T. Oxman,et al.  Treatment of minor depression. , 2002, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[9]  R. Ackermann,et al.  Rational treatment choices for non-major depressions in primary care , 2002, Journal of General Internal Medicine.

[10]  M. Lemke,et al.  Effect of reboxetine on depression in Parkinson's disease patients. , 2002, The Journal of clinical psychiatry.

[11]  S. Chiechio,et al.  The SSRI, Citalopram, Improves Bradykinesia in Patients With Parkinson's Disease Treated with L-Dopa , 2002, Clinical neuropharmacology.

[12]  I. Katz,et al.  The expert consensus guideline series. Pharmacotherapy of depressive disorders in older patients. , 2001, Postgraduate medicine.

[13]  G. Dell''Agnello,et al.  SSRIs Do Not Worsen Parkinson's Disease: Evidence from an Open-Label, Prospective Study , 2001, Clinical neuropharmacology.

[14]  M. Martens,et al.  Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson's disease. , 2001, The Journal of neuropsychiatry and clinical neurosciences.

[15]  Alex J. Sutton,et al.  Methods for Meta-Analysis in Medical Research , 2000 .

[16]  T. Bottiglieri,et al.  S‐adenosyl‐methionine improves depression in patients with Parkinson's disease in an open‐label clinical trial , 2000, Movement disorders : official journal of the Movement Disorder Society.

[17]  L. Murri,et al.  Paroxetine in Parkinson’s disease: Effects on motor and depressive symptoms , 2000, Neurology.

[18]  C. Mariani,et al.  Tolerability of paroxetine in Parkinson's disease: A prospective study , 2000, Movement disorders : official journal of the Movement Disorder Society.

[19]  Z. Rihmer Maria Satori Peter Pestality Selegiline-citalopram combination in patients with Parkinson's disease and major depression , 2000, International journal of psychiatry in clinical practice.

[20]  J. Cummings,et al.  Depression in patients with Parkinson's disease , 1999, International journal of geriatric psychiatry.

[21]  D. Deeg,et al.  Depression in Parkinson's disease. The impact of symptom overlap on prevalence. , 1998, Psychosomatics.

[22]  Roger Kurlan,et al.  A survey of antidepressant drug use in Parkinson's disease , 1997, Neurology.

[23]  R. Hauser,et al.  Sertraline for the treatment of depression in parkinson's disease , 1997, Movement disorders : official journal of the Movement Disorder Society.

[24]  J. Cummings,et al.  Risk factors for depression in Parkinson disease. , 1997, Archives of neurology.

[25]  Robert Rosenthal,et al.  Computing Contrasts, Effect Sizes, and Counternulls on Other People's Published Data: General Procedures for Research Consumers , 1996 .

[26]  I. Olkin,et al.  Improving the quality of reporting of randomized controlled trials. The CONSORT statement. , 1996, JAMA.

[27]  J. Cummings,et al.  The occurrence of depression in Parkinson's disease. A community-based study. , 1996, Archives of neurology.

[28]  G. Tollefson,et al.  A Double-Blind, Placebo-Controlled Clinical Trial of Fluoxetine in Geriatric Patients With Major Depression , 1995, International Psychogeriatrics.

[29]  T. Chase,et al.  Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging , 1992, Neurology.

[30]  M. Hietanen Selegiline and cognitive function in Parkinson's disease , 1991, Acta neurologica Scandinavica.

[31]  H. Allain,et al.  Selegiline in de novo parkinsonian patients: The French selegiline multicenter trial (FSMT) , 1991, Acta neurologica Scandinavica. Supplementum.

[32]  R G Robinson,et al.  Depression in Parkinson's Disease , 1990, The Journal of nervous and mental disease.

[33]  P. Carrieri,et al.  Amitriptyline in the treatment of headache in patients with Parkinson's disease , 1988, Neurology.

[34]  J. Yesavage,et al.  Geriatric Depression Scale (GDS): Recent evidence and development of a shorter version. , 1986 .

[35]  R. Mayeux,et al.  Clinical and biochemical features of depression in Parkinson's disease. , 1986, The American journal of psychiatry.

[36]  C. Tanner,et al.  Bupropion in Parkinson's disease , 1984, Neurology.

[37]  Y. Agid,et al.  Antiparkinsonian and antidepressant effects of high doses of bromocriptine. An independent comparison. , 1983, Journal of affective disorders.

[38]  A. Korczyn,et al.  DEPRENYL IN PARKINSON'S DISEASE , 1982, The Lancet.

[39]  J. Andersen,et al.  Anti‐depressive treatment in Parkinson's disease A CONTROLLED TRIAL OF THE EFFECT OF NORTRIPTYLINE IN PATIENTS WITH PARKINSON'S DISEASE TREATED WITH L‐DOPA , 1980, Acta neurologica Scandinavica.

[40]  M. Åsberg,et al.  A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.

[41]  C. Marsden,et al.  Nomifensine in Parkinson's disease. , 1977, British journal of clinical pharmacology.

[42]  G. Glass 9: Integrating Findings: The Meta-Analysis of Research , 1977 .

[43]  L. Laitinen DESIPRAMINE IN TREATMENT OF PARKINSON'S DISEASE , 1969 .

[44]  M. Macculloch,et al.  THE APPLICATION OF ANTICIPATORY AVOIDANCE LEARNING TO THE TREATMENT OF HOMOSEXUALITY. I. THEORY, TECHNIQUE AND PRELIMINARY RESULTS. , 1966, Behaviour research and therapy.

[45]  R. Strang Imipramine in Treatment of Parkinsonism: a Double-blind Placebo Study , 1965, British medical journal.

[46]  A. Beck,et al.  An inventory for measuring depression. , 1961, Archives of general psychiatry.

[47]  M. Hamilton A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[48]  Juan Carlos Espinosa,et al.  Comprehensive Meta-Analysis , 2004 .

[49]  A. Desautels,et al.  Effects of immobility on sensory and motor symptoms of restless legs syndrome , 2002, Movement disorders : official journal of the Movement Disorder Society.

[50]  M. Brin,et al.  Treatment of depression in idiopathic Parkinson's disease , 2022 .

[51]  P. Bech,et al.  a2-Adrenoreceptor antagonism and serotonin reuptake inhibition in patients with Parkinson disease and depression , 2000 .

[52]  P. Bech,et al.  Psychologic effects of structured cognitive psychotherapy in young patients with Parkinson disease: A pilot study , 1999 .

[53]  J. En,et al.  Combined and selective monoamine oxidase inhibition in the treatment of depression in Parkinson's disease. , 1999 .

[54]  E. J. Jansen Steur,et al.  Combined and selective monoamine oxidase inhibition in the treatment of depression in Parkinson's disease. , 1999, Advances in neurology.

[55]  P. Bech,et al.  Applicability and validity of the Major Depression Inventory in patients with Parkinson's disease , 1998 .

[56]  P. Bech,et al.  Depression in idiopathic Parkinson's disease treated with citalopram: A placebo-controlled trial , 1998 .

[57]  H. C. D. de Vet,et al.  Treatment of depression in Parkinson's disease: a meta-analysis. , 1995, The Journal of neuropsychiatry and clinical neurosciences.

[58]  E. Troisi,et al.  S-adenosylmethionine treatment of depression in patients with Parkinson's disease : a double-blind, crossover study versus placebo , 1990 .

[59]  H. Baas,et al.  Therapeutic efficacy of R-(-)-deprenyl as adjuvant therapy in advanced parkinsonism. , 1987, Journal of neural transmission. Supplementum.

[60]  H. Przuntek,et al.  The effect of R-(-)-deprenyl in de novo Parkinson patients on combination therapy with levodopa and decarboxylase inhibitor. , 1987, Journal of neural transmission. Supplementum.

[61]  R. Rosenthal Meta-analytic procedures for social research , 1984 .

[62]  J. Feighner,et al.  Diagnostic criteria for use in psychiatric research. , 1972, Archives of general psychiatry.

[63]  M. Lorr,et al.  Profile of mood states , 1971 .

[64]  W. Zung A SELF-RATING DEPRESSION SCALE. , 1965, Archives of general psychiatry.